Characterization of the tumor microenvironment in primary cutaneous CD30‐positive lymphoproliferative disorders: a predominance of CD163‐positive M2 macrophages. (8th May 2016)

• Record Type: Journal Article
• Authors: De Souza, Aieska; Tinguely, Marianne; Burghart, Daniel R.; Berisha, Arbeneshe; Mertz, Kirsten D.; Kempf, Werner
• Is Part Of: Journal of cutaneous pathology. Volume 43:Number 7(2016)
• Page Start: 579
• Page End: 588
• Publication Date: 2016-05-08
• Subjects: CD30‐positive lymphoproliferative disorders -- cutaneous lymphomas -- inflammatory microenvironment -- M2 macrophages -- programmed cell death 1; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616
• DOI: 10.1111/cup.12719
• Languages: English
• ISSNs: 0303-6987

Abstract

Abstract : Background: The tumor microenvironment is essential for tumor survival, growth and progression. There are only a few studies on the tumor microenvironment in cutaneous CD30‐positive lymphoproliferative disorders. Methods: We assessed the composition of the tumor microenvironment using immunohistochemistry studies in skin biopsies from cases diagnosed with lymphomatoid papulosis (LyP: 18 specimens), primary cutaneous anaplastic large‐cell lymphoma (PC‐ALCL: 8 specimens), and reactive diseases harboring CD30‐positive cells (18 specimens). Results: The predominant cells present in LyP and PC‐ALCL were CD163+ M2 macrophages (44.7%, 35%), followed by CD8+ tumor infiltrating lymphocytes (11%, 15%), FOXP3+ T‐regulatory cells (9%, 4.5%) and programmed cell death 1(PD‐1) + lymphocytes (2.2%, 6.8%). In contrast, CD30‐positive reactive inflammatory and infectious disorders were characterized by higher numbers of CD123+ plasmacytoid dendritic cells (6.3%) when compared to LyP (1%), and PC‐ALCL (1.1%). Conclusions: Key differences exist between the microenvironment of CD30‐positive lymphoproliferative disorders and reactive conditions harboring CD30‐positive lymphocytes. The high number of tumor associated macrophages, and the close vicinity of these immune cells to the CD30‐positive tumor cells might suggest that tumor associated macrophages have direct influence on tumorigenesis in LyP and ALCL. Therefore, modulation of M2 macrophages may represent a new therapeutic strategy in cutaneous CD30‐positive lymphoproliferative disorders.